{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:33:28Z","timestamp":1792701208728,"version":"4.5.0"},"reference-count":95,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Plasma cell leukemia (PCL) represents an exceptionally aggressive plasma cell malignancy defined by \u22655% circulating plasma cells in the peripheral blood of patients otherwise meeting the diagnostic criteria for multiple myeloma (MM), per the International Myeloma Working Group consensus. This ultrahigh-risk disease exhibits distinctive clinical features including frequent extramedullary involvement, severe cytopenias, hypercalcemia, renal insufficiency, and\/or significantly elevated \u03b22-microglobulin and lactate dehydrogenase levels. The molecular landscape includes high-risk cytogenetic abnormalities and mutations that promote accelerated proliferation, apoptotic resistance, immune evasion, and bone marrow microenvironmental independence through dysregulated adhesion molecule and chemokine receptor expression. Although autologous stem cell transplantation, proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies improved historical outcomes, the therapeutic paradigm continues to evolve. Novel therapeutic approaches including B-cell maturation antigen\u2013directed therapies (bispecific antibodies and chimeric antigen receptor T-cell therapy), G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted therapy, and B-cell lymphoma 2 (BCL-2) inhibition demonstrate promise in treating both primary and secondary PCL. Despite these advances, PCL remains inadequately studied, with treatment approaches predominantly extrapolated from MM trials in which patients with PCL have largely been excluded. This review synthesizes current evidence and presents illustrative clinical cases demonstrating practical treatment approaches, while highlighting critical knowledge gaps requiring dedicated prospective clinical trials to meaningfully improve outcomes in this challenging disease entity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032145","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:41:02Z","timestamp":1777660862000},"page":"403-416","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["How I treat plasma cell leukemia"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"Al Hadidi","sequence":"first","affiliation":[{"name":"1Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"2Myeloma Center, University of Arkansas for Medical Science, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026072311220485700_bib1","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","article-title":"How I treat plasma cell leukemia","volume":"120","author":"van de Donk","year":"2012","journal-title":"Blood"},{"key":"2026072311220485700_bib2","first-page":"336","article-title":"Myeloma und leucaemia lymphatica plasmocellularis [Myeloma and lymphatic plasmacytic leukemia]","volume":"12","author":"Gluzinski","year":"1906","journal-title":"Wien Klin Wochenschr"},{"issue":"5","key":"2026072311220485700_bib3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"issue":"7","key":"2026072311220485700_bib4","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdq646","article-title":"Primary plasma cell leukemia: a retrospective multicenter study of 73 patients","volume":"22","author":"Pagano","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"2026072311220485700_bib5","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2026072311220485700_bib6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma cell leukemia. Report on 17 cases","volume":"133","author":"Kyle","year":"1974","journal-title":"Arch Intern Med"},{"issue":"12","key":"2026072311220485700_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026072311220485700_bib8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026072311220485700_bib9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026072311220485700_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2026072311220485700_bib11","first-page":"2129","article-title":"Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study","volume":"110","author":"Singh","year":"2025","journal-title":"Haematologica"},{"issue":"3","key":"2026072311220485700_bib12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","article-title":"Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics","volume":"93","author":"Garc\u00eda-Sanz","year":"1999","journal-title":"Blood"},{"issue":"24","key":"2026072311220485700_bib13","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1002\/cncr.24700","article-title":"Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004","volume":"115","author":"Ramsingh","year":"2009","journal-title":"Cancer"},{"issue":"27","key":"2026072311220485700_bib14","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1200\/JCO.21.01217","article-title":"Identification of high-risk multiple myeloma with a plasma cell leukemia-like transcriptomic profile","volume":"40","author":"Hofste Op Bruinink","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026072311220485700_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"2026072311220485700_bib16","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"2026072311220485700_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.anndiagpath.2005.12.011","article-title":"Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation","volume":"10","author":"Johnson","year":"2006","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"2026072311220485700_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pathol.2021.09.011","article-title":"The many faces of plasma cell neoplasms: morphological and immunophenotypical variants of the great imitator","volume":"54","author":"El Hussein","year":"2022","journal-title":"Pathology"},{"issue":"10","key":"2026072311220485700_bib19","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ajh.27425","article-title":"Central nervous system multiple myeloma: a real-world multi-institutional study of the Greek Myeloma Study Group","volume":"99","author":"Katodritou","year":"2024","journal-title":"Am J Hematol"},{"issue":"2","key":"2026072311220485700_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-021-00414-6","article-title":"A clinical perspective on plasma cell leukemia; current status and future directions","volume":"11","author":"Tuazon","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026072311220485700_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41408-019-0253-1","article-title":"Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background","volume":"9","author":"Rojas","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026072311220485700_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41408-025-01442-2","article-title":"Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia","volume":"15","author":"Hellou","year":"2025","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026072311220485700_bib23","doi-asserted-by":"crossref","first-page":"2254556","DOI":"10.1080\/16078454.2023.2254556","article-title":"Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study","volume":"28","author":"Guan","year":"2023","journal-title":"Hematology"},{"issue":"8","key":"2026072311220485700_bib24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","article-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","volume":"5","author":"Ramberger","year":"2024","journal-title":"Nat Cancer"},{"issue":"11","key":"2026072311220485700_bib25","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2012.107","article-title":"Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols","volume":"26","author":"Usmani","year":"2012","journal-title":"Leukemia"},{"issue":"3","key":"2026072311220485700_bib26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/0008-5472.CAN-11-2781","article-title":"Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome","volume":"72","author":"Tiedemann","year":"2012","journal-title":"Cancer Res"},{"issue":"28","key":"2026072311220485700_bib27","doi-asserted-by":"crossref","first-page":"26129","DOI":"10.18632\/oncotarget.4674","article-title":"A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias","volume":"6","author":"Lionetti","year":"2015","journal-title":"Oncotarget"},{"issue":"7339","key":"2026072311220485700_bib28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"2026072311220485700_bib29","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"8","key":"2026072311220485700_bib30","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2016.366","article-title":"Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma","volume":"31","author":"Mithraprabhu","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"2026072311220485700_bib31","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-12-2043","article-title":"Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia","volume":"19","author":"Lionetti","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"35","key":"2026072311220485700_bib32","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2026072311220485700_bib33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"2026072311220485700_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2141.1991.tb08050.x","article-title":"Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells","volume":"79","author":"Van Riet","year":"1991","journal-title":"Br J Haematol"},{"issue":"8","key":"2026072311220485700_bib35","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1182\/blood.V84.8.2597.2597","article-title":"Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells","volume":"84","author":"Pellat-Deceunynck","year":"1994","journal-title":"Blood"},{"issue":"suppl 1","key":"2026072311220485700_bib36","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1182\/blood-2023-187527","article-title":"Single-cell RNA sequencing identifies distinct immune microenvironment in patients with primary plasma cell leukemia [abstract]","volume":"142","author":"Cho","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2026072311220485700_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-020-0336-z","article-title":"Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns","volume":"10","author":"Schinke","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026072311220485700_bib38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bjh.15092","article-title":"Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients","volume":"180","author":"Jurczyszyn","year":"2018","journal-title":"Br J Haematol"},{"issue":"17","key":"2026072311220485700_bib39","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood.2021014968","article-title":"Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features","volume":"139","author":"Cazaubiel","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2026072311220485700_bib40","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2026072311220485700_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.58877\/japaj.v1i3.85","article-title":"Tumor lysis syndrome: pathophysiology, risk factors, management strategies, and prognostic indicators","volume":"1","author":"Al-Abbadi","year":"2023","journal-title":"JAPA Acad J"},{"issue":"12","key":"2026072311220485700_bib42","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1080\/10428194.2022.2092856","article-title":"Thromboprophylaxis in multiple myeloma","volume":"63","author":"Thalambedu","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026072311220485700_bib43","doi-asserted-by":"crossref","first-page":"100999","DOI":"10.1016\/j.blre.2022.100999","article-title":"The use of bone-modifying agents in multiple myeloma","volume":"57","author":"Hussain","year":"2023","journal-title":"Blood Rev"},{"issue":"1","key":"2026072311220485700_bib44","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2024000579","article-title":"Supportive care in myeloma-when treating the clone alone is not enough","volume":"2024","author":"Zweegman","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"2026072311220485700_bib45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2026072311220485700_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.58877\/japaj.v1i1.21","article-title":"Primary plasma cell leukemia","volume":"1","author":"Al Hadidi","year":"2023","journal-title":"JAPA Acad J"},{"issue":"23","key":"2026072311220485700_bib47","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026072311220485700_bib48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/leu.2013.241","article-title":"Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia","volume":"28","author":"Musto","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"2026072311220485700_bib49","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/cncr.22700","article-title":"Efficacy and safety of bortezomib in patients with plasma cell leukemia","volume":"109","author":"Musto","year":"2007","journal-title":"Cancer"},{"issue":"18","key":"2026072311220485700_bib50","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026072311220485700_bib51","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study","volume":"24","author":"van de Donk","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026072311220485700_bib52","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.26891","article-title":"Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: a multicenter study by the Greek Myeloma Study Group","volume":"98","author":"Katodritou","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"2026072311220485700_bib53","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2021.01.002","article-title":"Efficacy of daratumumab-based regimens for the treatment of plasma cell leukemia","volume":"21","author":"Parrondo","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026072311220485700_bib54","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/annonc\/mdr480","article-title":"Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party","volume":"23","author":"D'Arena","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"2026072311220485700_bib55","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/leu.2011.312","article-title":"Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research","volume":"26","author":"Mahindra","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"2026072311220485700_bib56","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","article-title":"Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era","volume":"34","author":"Dhakal","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2026072311220485700_bib57","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"2026072311220485700_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"2026072311220485700_bib59","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1200\/JCO-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026072311220485700_bib60","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026072311220485700_bib61","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"2026072311220485700_bib62","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026072311220485700_bib63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-024-01030-w","article-title":"Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk","volume":"14","author":"Callander","year":"2024","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026072311220485700_bib64","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2019-131887","article-title":"Early results of TOTAL therapy 7 (TT7): high response rates of newly diagnosed high risk myeloma to daratumumab [abstract]","volume":"134","author":"van Rhee","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2026072311220485700_bib65","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/ajh.27314","article-title":"Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"99","author":"Costa","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"2026072311220485700_bib66","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2025.1394","article-title":"Long-term follow-up of patients with multiple myeloma treated on earlier total therapy protocols: a secondary analysis of 3 clinical trials","volume":"11","author":"Al Hadidi","year":"2025","journal-title":"JAMA Oncol"},{"issue":"9","key":"2026072311220485700_bib67","first-page":"572","article-title":"High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma","volume":"28","author":"Ali","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2026072311220485700_bib68","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"issue":"23","key":"2026072311220485700_bib69","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2026072311220485700_bib70","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.20272","article-title":"Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature","volume":"78","author":"Saccaro","year":"2005","journal-title":"Am J Hematol"},{"issue":"21","key":"2026072311220485700_bib71","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1182\/blood.V118.21.2008.2008","article-title":"Has allogeneic transplantation a role in the management of plasma cell leukaemia? A study on behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT","volume":"118","author":"Morris","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026072311220485700_bib72","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-023-00900-z","article-title":"Long-term outcomes of allogeneic stem cell transplant in multiple myeloma","volume":"13","author":"Schmidt","year":"2023","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026072311220485700_bib73","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.ymthe.2024.05.039","article-title":"Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies","volume":"32","author":"Al Hadidi","year":"2024","journal-title":"Mol Ther"},{"issue":"17","key":"2026072311220485700_bib74","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026072311220485700_bib75","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"2026072311220485700_bib76","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"2026072311220485700_bib77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/hematology.2021000231","article-title":"Treatment of older adult or frail patients with multiple myeloma","volume":"2021","author":"Grant","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2026072311220485700_bib78","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/OTT.S370880","article-title":"Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives","volume":"16","author":"Shrivastava","year":"2023","journal-title":"Onco Targets Ther"},{"issue":"6","key":"2026072311220485700_bib79","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"2026072311220485700_bib80","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2026072311220485700_bib81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ejh.12986","article-title":"Combination therapy incorporating Bcl-2 inhibition with venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026072311220485700_bib82","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1002\/ajh.25331","article-title":"Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)","volume":"94","author":"Jelinek","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2026072311220485700_bib83","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/bjh.18243","article-title":"How do we manage t(11;14) plasma cell disorders with venetoclax?","volume":"199","author":"Chakraborty","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"2026072311220485700_bib84","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ajh.20672","article-title":"VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia","volume":"81","author":"Ataergin","year":"2006","journal-title":"Am J Hematol"},{"issue":"7","key":"2026072311220485700_bib85","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1080\/10428190701370597","article-title":"Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia","volume":"48","author":"Ali","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026072311220485700_bib86","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2141.2012.09029.x","article-title":"Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia","volume":"157","author":"Gozzetti","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"2026072311220485700_bib87","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/1078155219895072","article-title":"A successful case of venetoclax-based therapy in relapsed\/refractory secondary plasma cell leukemia","volume":"26","author":"Kupsh","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"2026072311220485700_bib88","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clml.2024.10.014","article-title":"Clinical characteristics and survival outcomes of patients with primary and secondary plasma cell leukemia according to the 2021 definition: a single center retrospective study","volume":"25","author":"Shalaby","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"2026072311220485700_bib89","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1182\/bloodadvances.2025016695","article-title":"The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia","volume":"9","author":"Shrestha","year":"2025","journal-title":"Blood Adv"},{"issue":"23","key":"2026072311220485700_bib90","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2025016966","article-title":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia","volume":"9","author":"Galarza Fortuna","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026072311220485700_bib91","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2025-823","article-title":"Real world outcomes of bispecific T-cell engagers in plasma cell leukemia [abstract]","volume":"146","author":"Gaballa","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026072311220485700_bib92","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1182\/blood-2025-1036","article-title":"Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia [abstract]","volume":"146","author":"Packard","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026072311220485700_bib93","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1182\/blood-2025-4067","article-title":"CART\u2013ASCT\u2013CART2 sandwich regimen as frontline therapy: a phase II trial in patients with primary plasma cell leukemia [abstract]","volume":"146","author":"Xu","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026072311220485700_bib94","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.annonc.2025.01.022","article-title":"European Myeloma Network Group review and consensus statement on primary plasma cell leukemia","volume":"36","author":"Musto","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"2026072311220485700_bib95","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2025-257","article-title":"BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: an open label, single-arm, phase 2 study (CAREMM-002) [abstract]","volume":"146","author":"Yan","year":"2025","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/4\/403\/2534461\/blood_bld-2025-032145-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/4\/403\/2534461\/blood_bld-2025-032145-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:22:19Z","timestamp":1784820139000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/4\/403\/568165\/How-I-treat-plasma-cell-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032145","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,23]]},"published":{"date-parts":[[2026,7,23]]}}}